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1. Supporting Figures 
 
 
 
 
 
 
 
 
Figure S1. Binding of RANTES to heparin, as determined by ELISA. Heparin-binding 96-well 
plates were coated with heparin (25 g/mL; 20-kDa). Human RANTES (1 – 1024 nM; ) was 
serially diluted and then incubated in the heparin-coated plates. For ELISA analysis, RANTES 
was first incubated with a mouse anti-RANTES primary antibody and then with a goat anti-
mouse IgG antibody conjugated to horseradish peroxidase (HRP). Levels of plate-bound 
RANTES were measured by detecting HRP activity at 450 nm. Data were fitted to a sigmoidal 
curve to determine the half-maximal effective concentration (EC50) for RANTES binding to 
heparin. Experiments were conducted in quadruplicate, and the standard error is depicted.  
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Figure S2. Glycopolymers 1 – 4 do not potentiate inhibition of thrombin in a purified system 
with antithrombin III. Human antithrombin III (1 IU/mL) was incubated with an excess of 
thrombin (24 IU/mL) in the presence of either heparin or glycopolymer (10
-5
 – 500 g/mL). 
Heparin is known to bind to and induce a conformation change in the structure of antithrombin 
III, thereby increasing its inhibitory activity for thrombin (as observed in this assay). A 
chromogenic substrate (1.25 umol/mL) specific for the proteolytic activity of thrombin was added 
to measure residual levels of thrombin in the mixture. The absorbance was measured at 405 nm 
and is inversely proportional to the ability of heparin or glycopolymer to potentiate the inhibitory 
activity of antithrombin III. Data represent the mean ± standard error for quadruplicate assays.     
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Figure S3. RANTES-induced migration of CCR3- and CCR5-expressing cells. Chemotactic 
response to RANTES is maximal at (a) 10 nM for CCR3-stably transfected L1.2 cells and (b) 1 
nM for CCR5-stably transfected L1.2 cells. In both experiments, wild-type L1.2 cells did not 
migrate in response to RANTES as expected. Chemotaxis was measured using a 96-well 
modified Boyden chamber, and the relative number of migrated cells was determined using a 
fluorescent nucleic acid dye. Data represent the mean ± standard error for two independent 
experiments, each conducted in quadruplicate.     
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Figure S4. RANTES binding to CCR3-expressing cells. RANTES (100 nM) was preincubated 
with varying concentrations of heparin or glycopolymer 1 (0.02 – 2 g/mL). Heparin or 1 inhibits 
the binding of RANTES to L1.2-CCR3 cells, as determined by flow cytometry (*, P < 0.05; 
means were compared to RANTES treatment alone using a Student’s t test). Data represent the 
mean  standard error for three independent experiments, each conducted in quadruplicate. 
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Figure S5. RANTES-induced migration of CCR5-expressing cells. RANTES (1 nM) was added 
to the bottom half of a 96-well modified Boyden chamber and pre-incubated with various 
concentrations of heparin or glycopolymer 1 prior to chemotaxis induction. The relative number 
of migrated cells was measured using a fluorescent nucleic acid dye. Heparin and 1 did not affect 
the migration of L1.2-CCR5 cells, except at the highest concentration of 1 (4 g/mL; *, P < 0.01; 
means were compared to RANTES treatment alone using a Student’s t test). Experiments were 
conducted in quadruplicate, and the standard error is depicted. 
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2. Supporting Tables 
 
 
 
Table S1.  Properties of glycopolymers 1 – 4. 
 
Polymer 
 
Monomer 
mol% 
Catalyst  
Mn
a 
(g/mol) 
 
PDIa 
n  
(DP b) 
1 22 5 27,870 1.22 35 
2 23 5 36,490 1.02 48 
3 24 5 53,580 1.16 90 
4 25 5 32,880 1.03 46 
 
a  
Number average molecular weight (Mn) and polydispersity index (PDI) were 
determined by size exclusion chromatography multi-angle light scattering 
(SEC-MALS).  
b 
Degree of polymerization (DP).  Despite equal mol% of catalyst, the DP was 
notably higher for unsulfated monomer 24. This was likely due to increased 
solubility of the unsulfated polymer (3) in the polymerization co-solvent (10:1 
dichloroethane/methanol) compared to the sulfated polymers (1, 2, and 4). 
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Table S2.  Half maximal inhibitory concentration (IC50) for antagonists of RANTES 
 
Antagonist 
IC50 
(g/mL)a 
IC50 
(nM)b  
IC50 
(g/mL  
of disac)c 
IC50 
(M  
of disac)d 
1 9.3 ± 1.1 334 ± 39 6.8 ± 0.80 11.7 ± 1.4 
2 31.1 ± 6.2 852 ± 170 21.8 ± 4.4 40.3 ± 8.0 
4 58.0 ± 5.7 1760 ± 170 40.6 ± 4.0 81.3 ± 8.0 
Heparin 0.90 ± 0.03 45.0 ± 1.5 0.90 ± 0.03 1.50 ± 0.05 
 
a
  Values were determined from Figure 1 using KaleidaGraph software. Data 
represent the mean ± standard error for quadruplicate assays. 
b
 Values were calculated from Figure 1 based on molar concentration of 
antagonist (see Table S1 for molecular weights of polymers 1-4). 
c
 Values were corrected for ligand valence after taking into account the mass 
percentage of disaccharide contributing to each disaccharide-norbornyl linker 
unit. 
d
 Values were corrected for ligand valence based on molar concentration of 
disaccharide.  
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3. Experimental Methods 
 
 
3-1. General Synthetic Procedures  
Unless stated otherwise, reactions were performed in flame-dried glassware under an argon 
atmosphere using freshly dried solvents. Solvents were dried via passage through an activated 
alumina column under argon. All other commercially obtained reagents were used as received 
unless otherwise noted. Thin-layer chromatography (TLC) was performed using E. Merck silica 
gel 60 F254 pre-coated plates (0.25 mm). Visualization of the chromatogram was accomplished 
by UV, cerium ammonium molybdate or ninhydrin staining as necessary. ICN silica gel (particle 
size 0.032 – 0.063 mm) was used for flash chromatography. Gel filtration chromatography was 
also used in order to achieve purification of the final products.    
 
1
H and 
13
C NMR experiments were recorded on Varian Mercury 300 (at 300 MHz), 
Varian Inova 500 (at 500 MHz), or Varian Inova 600 (600 MHz) spectrometers and are reported 
in parts per million () relative to CDCl3 (7.26 ppm) or CD3OD (4.80 ppm). Data for 
1
H are 
reported as follows: chemical shift ( ppm), multiplicity (s = singlet, d = doublet, t = triplet, q = 
quartet, m = multiplet), coupling constant in Hz, and integration. 
13
C NMR spectra were obtained 
on Varian Inova 500 (at 125 MHz) or Varian Inova 600 (at 150 MHz) spectrometers and are 
reported in terms of chemical shift (77.2 ppm for CDCl3; 49.0 for CD3OD). When necessary, 
proton and carbon assignments were made by means of 
1
H-
1
H gCOSY, 
1
H-
1
H TOCSY, and 
1
H-
13
C gHSQCAD. Stereochemical assignments are supported by 
1
H-
1
H ROESY spectra. Mass 
spectra were obtained using a Perkin Elmer/Sciex API 365 triple quadrupole/electrospray tandem 
mass spectrometer or a Waters LCT Premier XE high resolution mass spectrometer. 
 
3-2. Synthesis of Compounds and Assignments  
 
 
Methyl 3-O-benzyl-L-idopyranosyluronate (9). Compound 9 was prepared in six steps from the 
commercially available diacetone glucose (Sigma Aldrich) using previously reported procedures.
1
 
The analytical data were in agreement with the reported spectra. 
 
 
O
OHOH
OBn
MeO2C
OH
O
OAcOAc
OBn
MeO2C OAc
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Methyl 1,2,4-tri-O-acetyl-3-O-benzyl--L-idopyranosyluronate (10). Compound 9 (0.30 g, 1.0 
mmol) was added to CH2Cl2 (5.5 mL) at 0 C, and the solution was cooled to -40 C. 4-
Dimethylaminopyridine (120 mg, 0.10 mmol) was added, followed by pyridine (700 L, 10 
mmol). Acetyl chloride (470 L, 6.0 mmol) was then added dropwise to the reaction mixture, 
which was stirred for 10 h at -40 C. The reaction was quenched with aqueous NaHCO3 (50 mL), 
extracted with CH2Cl2 (2.0 x 50 mL), and subsequently washed with H2O, 1M H2SO4, and then 
H2O (50 mL for each wash). The combined organic layers were dried over MgSO4 and 
concentrated under reduced pressure. Purification by silica gel flash chromatography (3:1 
hexanes:EtOAc) afforded compound 10 (0.40 g) in quantitative yield. The analytical data were in 
agreement with previously reported spectra.
3
 ESI-TOF HRMS: m/z calcd for C20H23O10 [M+H]-
H2 423.1286; found: 423.1286.   
 
 
Methyl 4-O-acetyl-3-O-benzyl--L-idopyranuronate 1,2-(methyl-orthoacetate) (11). TiBr4 
(8.1 g, 22 mmol) was added to a solution of compound 10 (6.9 g, 16 mmol) in CH2Cl2 (360 mL), 
and the reaction was stirred for 16 h at ambient temperature with exclusion of light. The reaction 
was quenched with ice-cold H2O (2.0 x 500 mL), filtered through Celite, and concentrated under 
reduced pressure. The resulting brown oil was immediately used in the next reaction without 
further purification. The crude bromide intermediate (16 mmol) was dissolved in CH2Cl2 (220 
mL). 2,4,6-Collidine (11 mL, 80 mmol) and methanol (8.0 mL) were added to this solution, and 
the reaction was stirred for 14 h at room temperature (rt). The reaction mixture was then diluted 
with CH2Cl2 (500 mL), washed with aqueous NaHCO3 and H2O (200 mL each), dried over 
MgSO4, and concentrated under reduced pressure. Purification by silica gel flash chromatography 
(6:1 hexanes:EtOAc + 1% Et3N) afforded 11 (7.6 g, 75% over 2 steps) as a light yellow oil. 
1
H 
NMR (500 MHz; CDCl3):  7.44 – 7.30 (m, 5H, OCH2Ph), 5.57 (d, J = 2.7 Hz, 1H, H-1), 5.20 
(dt, J = 2.7, 1.3 Hz, 1H, H-4), 4.82 (d, J = 11.7 Hz, 1H, OCH2Ph), 4.69 (d, J = 11.7 Hz, 1H, 
OCH2Ph), 4.56 (d, J = 1.4 Hz, 1H, H-5), 4.15 (dd, J = 2.7, 1.9 Hz, 1H, H-3), 4.09 (ddd, J = 2.9, 
1.9, 1.2 Hz, 1H, H-2), 3.79 (s, 3H, CO2CH3), 3.26 (s, 3H, OCH3), 2.05 (s, 3H, OCOCH3), 1.74 (s, 
3H, CH3); 
13
C NMR (125 MHz; CDCl3):  170.1, 168.1, 136.8, 128.6, 128.4, 128.0, 96.6, 77.3, 
76.1, 72.9, 71.3, 69.6, 68.9, 52.6, 49.1, 25.0, 20.1; ESI-TOF HRMS: m/z calcd for C19H23O9 
[M+H]-H2 395.1342; found: 395.1354.   
 
O
OAc
OBn
MeO2C
O
O
OMe
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Methyl 3-O-benzyl--L-idopyranuronate 1,2-(methyl-orthoacetate) (12). Compound 11 (7.2 
g, 18 mmol) was dissolved in methanol (90 mL) and cooled to -10 C. A 0.5 M solution NaOMe 
(1.8 mL, 0.91 mmol) was added, and the reaction mixture was stirred at -10 C for 2 h and at 5 C 
overnight. The solution was diluted with CH2Cl2 (200 mL) at 5 C, quenched with aqueous 
NaHCO3 and H2O (500 mL each), and then extracted with (3.0 x 250 mL). The organic fractions 
were dried over MgSO4 and concentrated under reduced pressure. Purification by silica gel flash 
chromatography (4:1  1:1 hexanes:EtOAc + 1% Et3N) yielded 12 (9.5 g, 80%) as a clear oil. 
1
H 
NMR (500 MHz; CDCl3):  7.36 – 7.34 (m, 5H, OCH2Ph), 5.51 (d, J = 2.4 Hz, 1H, H-1), 4.72 (d, 
J = 11.7 Hz, 1H, OCH2Ph), 4.62 (d, J = 11.7 Hz, 1H, OCH2Ph), 4.52 (s, 1H, H-4), 4.15 – 4.08 (m, 
3H, H-2, H-5), 3.81 (s, 3H, CO2CH3), 3.30 (s, 3H, OCH3), 2.78 (d, J = 11.4 Hz, 1H, H-3), 1.76 (s, 
3H, CH3); 
13
C NMR (125 MHz; CDCl3):  168.3, 136.8, 128.7, 128.4, 127.9, 96.8, 75.8, 73.0, 
72.9, 71.8, 67.0, 52.5, 50.3, 24.4; ESI-TOF HRMS: m/z calcd for C17H21O8 [M+H]-H2 353.1236; 
found: 353.1226.   
 
 
Methyl 3-O-benzyl-4-O-tert-butyldimethylsilyl--L-idopyranuronate 1,2-(methyl-orthoace-
tate) (13). Compound 12 (230 mg, 0.64 mmol) was dissolved in pyridine (7.8 mL) and the 
solution was cooled to -10 C. TBSOTf (1.5 mL, 0.65 mmol) was added, and the reaction was 
stirred overnight at 0 C. The reaction was diluted with CH2Cl2 (100 mL), quenched with aqueous 
NaHCO3 (100 mL), and extracted with EtOAc (3.0 x 50 mL). The combined organic fractions 
were dried over MgSO4 and concentrated under reduced pressure. Purification by silica gel flash 
chromatography (7:1 hexanes:EtOAc + 1% Et3N) yielded compound 32 (380 mg, 92%) as a clear 
oil. 
1
H NMR (500 MHz; CDCl3):  7.47 (m, 5H, OCH2Ph), 5.62 (d, J = 2.5 Hz, 1H, H-1), 4.80 (d, 
J = 12 Hz, 1H, OCH2Ph), 4.75 (d, J = 12 Hz, 1H, OCH2Ph), 4.51 (s, 1H, H-4), 4.21 (s, 1H, H-5), 
4.20 (d, J = 1 Hz, 1H, H-4), 3.98 (s, 1H, H-3), 3.89 (s, 3H, CO2CH3), 3.40 (s, 3H, OCH3), 1.84 (s, 
3H, CH3), 0.94 (s, 9H, SiC(CH3)3), 0.08 (s, 3H, SiCH3), 0.06 (s, 3H, SiCH3); 
13
C NMR (125 
MHz; CDCl3):  169.6, 137.0, 128.9, 128.6, 128.2, 124.6, 97.1, 76.3. 74.6, 72.8, 72.5, 67.9, 52.4, 
49.5, 29.9, 25.7, 25.6, -4.4, -5.2; TOF HRMS ES m/z calcd for C23H36O8SiNa [M+Na]
+
: 
491.2077; found: 491.2070.  
O
OH
OBn
MeO2C
O
O
OMe
O
OTBS
OBn
MeO2C
O
O
OMe
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Methyl (dibutylphosphate-2-O-acetyl-3-O-benzyl-4-O-tert-butyldimethylsilyl--L-idopyra-
nosid)uronate (6). Compound 13 (140 mg, 0.29 mmol) was dissolved in CH2Cl2 (7.3 mL) at rt. 
Freshly activated 4Å molecular sieves (290 mg) were added, and the solution was stirred for 15 
min. Dibutylphosphate (0.54 mL, 2.9 mmol) was added slowly, and the reaction mixture was 
stirred overnight. After confirming that the reaction was complete by TLC, the reaction was 
quenched with triethylamine (2.0 mL) and concentrated under reduced pressure. Silica gel flash 
chromatography (5:1  3:1 hexanes:EtOAc + 1% Et3N) afforded the desired product (170 mg) in 
quantitative yield. 
1
H NMR (500 MHz; CDCl3):  7.36 – 7.35 (m, 5H, OCH2Ph), 5.82 (d, J = 7.2 
Hz, 1H, H-1), 4.97 (m, 1H, H-2), 4.86 (d, J = 2.7 Hz, 1H, H-5), 4.78 (d, J = 12 Hz, 1H, OCH2Ph), 
4.62 (d, J = 12 Hz, 1H, OCH2Ph), 4.09 – 3.99 (m, 5H, H-4, P(OCH2CH2CH3)2), 3.77 (s, 3H, 
CO2CH3), 3.62 (m, 1H, H-3), 2.04 (s, 3H, COCH3), 1.64 – 1.60 (m, 4H, P(OCH2CH2CH2CH3)2), 
1.40 – 1.25 (m, 4H, P(OCH2CH2CH2CH3)2), 0.96 – 0.88 (m, 6H, P(OCH2CH2CH2CH3)2), 0.81 (s, 
9H, SiC(CH3)3), 0.07 (s, 3H, SiCH3), 0.17 (s, 3H, SiCH3); 
13
C NMR (125 MHz; CDCl3):  169.8, 
169.2, 146.6, 137.3, 128.4, 128.0, 95.4, 73.8, 72.0, 68.0, 67.8, 67.0, 66.9, 52.1, 32.1, 25.4, 20.9, 
18.6, 17.8, 13.5, -4.7, -5.7; ESI-TOF HRMS m/z calcd for C30H52O11PSi [M+H]
+
: 647.3017; 
found: 647.3001. 
 
 
2-O-Azido-3-O-benzyl-6-O-levulinoyl-1-O-tert-butyldimethylsilyl-2-deoxy--D-glucopyrano-
side (7). Compound 7 was prepared from readily available D-glucosamine (Sigma Aldrich) using 
previously published procedures, and the analytical data were in agreement with previously 
reported spectra.
1
 
 
 
2-(2-((2S)-bicyclo[2.2.1]hept-5-en-2-ylmethoxy)ethoxy)ethanol (8). Compound 8 was prepared 
using a previously published procedure, and the analytical data were in agreement with reported 
spectra.
2
 
 
O
OTBS
OBn
MeO2C
OAc
OPO(OBu)2
O
OLev
HO
BnO
N3
OTBS
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Methyl 2-O-acetyl-3-O-benzyl-4-O-tert-butyldimethylsilyl--L-idopyranosyluronate-(14)-
tert-butyldimethylsilyl (2-azido-3-O-benzyl-6-O-levulinoyl-2-deoxy--D-glucopyranoside) 
(14). Compound 6 (92 mg, 0.14 mmol) and 7 (77 mg, 0.17 mmol) were co-evaporated with 
toluene (3.0 x 1.0 mL) and placed under vacuum overnight. The mixture was dissolved in CH2Cl2 
(4.2 mL), and freshly activated 4Å molecular sieves (0.21 g) were added. After stirring at rt for 
15 min, the temperature was lowered to -10 C and the mixture stirred for an additional 15 min. 
TMSOTf (31 L, 0.18 mmol) was added dropwise to the reaction mixture. The reaction was 
stirred at -30 C for 30 min, quenched with Et3N (1.0 mL), filtered through a silica pad, and 
concentrated under reduced pressure. Silica gel flash chromatography (5:1  4:1 
hexanes:EtOAc) afforded the desired product (120 mg) in 93% yield. 
1
H NMR (600 MHz; 
CDCl3):  7.37 – 7.24 (m, 10H, OCH2Ph), 5.20 (d, J = 4.2 Hz, 1H, H-1 of IdoA), 4.85 (t, J = 4.1 
Hz, 1H, H-2 of IdoA), 4.82 (d, J = 10.6 Hz, 1H, OCH2Ph), 4.74 (d, J = 11.8 Hz, 1H, OCH2Ph), 
4.71 (d, J = 10.8 Hz, 1H, OCH2Ph), 4.69 (d, J = 3.9 Hz, 1H, H-5 of IdoA), 4.64 (d, J = 11.8 Hz, 
1H, OCH2Ph), 4.54 (dd, J = 11.8, 2.1 Hz, 1H, H-1 of GlcN), 4.51 – 4.45 (m, 1H, H-6), 4.20 – 
4.03 (m, 1H, H-6), 3.99 (t, J = 4.3 Hz, 1H, H-4 of IdoA), 3.91 – 3.77 (m, 1H, H-4 of GlcN), 3.61 
(t, J = 4.3 Hz, 1H, H-3 of IdoA), 3.54 (s, 3H, CO2CH3), 3.48 (ddd, J = 9.8, 5.9, 2.2 Hz, 1H, H-5 
of GlcN), 3.37 – 3.24 (m, 2H, H-2 and H-3 of GlcN), 2.89 – 2.66 (m, 2H, COCH2CH2COCH3), 
2.61 (t, J = 6.7 Hz, 2H, COCH2CH2COCH3), 2.19 (s, 3H, COCH2CH2COCH3), 2.00 (s, 3H, 
COCH3), 0.92 (s, 9H, SiC(CH3)3), 0.81 (s, 9H, SiC(CH3)3), 0.13 (d, J = 4.6 Hz, 6H, SiCH3), -0.06 
(s, 3H, SiCH3), -0.12 (s, 3H, SiCH3); 
13
C NMR (125 MHz; CDCl3):  206.5, 172.2, 170.2, 169.9, 
138.2, 137.7, 128.5, 128.1, 128.1, 127.9, 127.4, 97.6, 97.1, 80.6, 76.8, 76.5, 75.4, 74.8, 73.4, 72.7, 
71.5, 69.9, 68.9, 68.5, 62.6, 51.7, 38.0, 29.9, 28.0, 25.6, 25.5, 20.9, 18.0, 17.8, -4.3, -4.7, -5.2, -
5.5; ESI-TOF HRMS m/z calcd for C46H69N3O14Si2 [M+Na]
+
: 966.4216; found: 966.4211. 
 
 
Methyl 2-O-acetyl-3-O-benzyl-4-O-tert-butyldimethylsilyl--L-idopyranosyluronate-(14)-
2-azido-3-O-benzyl-1-O-(2-(2-((2S)-bicyclo[2.2.1]hept-5-en-2-yl-methoxy)ethoxy)ethyl)-6-O-
levulinoyl-2-deoxy--D-glucopyranoside (5). Compound 15 (37 mg, 60 mol) and 8 (33 mg, 70 
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mol) were co-evaporated with toluene (3.0 x 1.0 mL) and placed under vacuum overnight. The 
mixture was dissolved in CH2Cl2 (1.7 mL) and freshly activated 4Å molecular sieves (80 mg) 
were added. After stirring at rt for 15 min, the temperature was lowered to -30 C and the mixture 
stirred for an additional 15 min. TMSOTf (14 L, 70 mol) was added to dropwise to the 
reaction mixture. The reaction was stirred at -10 C for 10 min, slowly raised to rt over 15 min, 
quenched with Et3N (0.50 mL), filtered through a silica pad, and concentrated under reduced 
pressure. Silica gel flash chromatography (10:1  4:1  3:1 hexanes:EtOAc) afforded the 
desired product (35 mg) in 67% yield. 
1
H NMR (500 MHz; CDCl3):  7.38 – 7.25 (m, 10H, 
OCH2Ph), 6.07 (ddd, J = 25.6, 5.7, 3.0 Hz, 2H, CH=CH of Nb), 5.19 (d, J = 4.2 Hz, 1H, H-1 of 
IdoA), 4.89 – 4.79 (m, 2H, H-2 of IdoA, OCH2Ph), 4.72 – 4.68 (m, 3H, H-5 of IdoA, OCH2Ph), 
4.64 (d, J = 11.9 Hz, 1H, OCH2Ph), 4.52 (dd, J = 12.1, 2.2 Hz, 1H, H-6 of GlcN), 4.34 (d, J = 7.9 
Hz, 1H, H-1 of GlcN), 4.12 (dd, J = 12.1, 2.2 Hz, 1H, H-6 of GlcN), 4.02 – 3.93 (m, 2H, H-4 of 
IdoA, OCH2 of PEG linker), 3.87 (dd, J = 9.8, 8.9 Hz, 1H, H-4 of GlcN), 3.82 – 3.55 (m, 5H, H-3 
of IdoA, OCH2 of PEG linker), 3.54 (s, 3H, CO2CH3), 3.53 – 3.29 (m, 5H, H-5 of GlcN, H-2 of 
GlcN, H-3 of GlcN, OCH2 of PEG linker), 2.88 – 2.67 (m, 4H, CH-CH=CH of Nb, 
COCH2CH2COCH3), 2.67 – 2.56 (m, 2H, COCH2CH2COCH3), 2.19 (s, 3H, COCH2CH2COCH3), 
2.00 (s, 3H, OCOCH3), 1.75 – 1.66 (m, 1H, CH of Nb), 1.39 – 1.15 (m, 4H, CH2 of Nb), 0.81 (s, 
9H, SiC(CH3)), -0.06 (s, 3H, SiCH3), -0.11 (s, 3H, SiCH3); 
13
C NMR (125 MHz; CDCl3):  136.6, 
128.5, 128.2, 127.8, 102.2, 80.9, 76.8, 76.1, 75.0, 73.2, 72.9, 71.6, 70.7, 70.4, 66.0, 45.0, 43.6, 
38.8, 38.0, 29.8, 28.1, 25.5; ESI-TOF HRMS m/z calcd for C52H73N3O16Si [M+Na]
+
: 1046.4658; 
found: 1046.4670 
 
 
Methyl 2-O-acetyl-3-O-benzyl-4-O-tert-butyldimethylsilyl--L-idopyranosyluronate-(14)-
2-azido-3-O-benzyl-6-O-levulinoyl-2-deoxy--D-glucopyranosyl trichloroacetimidate (15). 
Compound 14 (840 mg, 0.89 mmol) was dissolved in THF (27 mL) and the solution was cooled 
to 0 C. 1M TBAF (1.2 mL, 1.2 mmol) and AcOH (60 L, 1.1 mmol) were added 
simultaneously, and the reaction was stirred for 30 min at 0 C. The reaction was quenched with 
aqueous NaHCO3 (10 mL), extracted with CH2Cl2 (2.0 x 10 mL), and subsequently washed with 
H2O, 1M H2SO4, and then H2O (10 mL for each wash). After concentrating under reduced 
pressure, the crude mixture (0.89 mmol) was dissolved in CH2Cl2 (27 mL) and cooled to 0 C. To 
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the reaction mixture, trichloroacetonitrile (1.3 mL, 13 mmol) and DBU (26 L, 0.18 mmol) were 
added. The reaction was stirred at 0 C for 12 h, quenched with Et3N (1.0 mL), and concentrated 
under reduced pressure. Silica gel flash chromatography (5:1  4:1  3:1 hexanes:EtOAc + 1% 
Et3N) afforded the desired product (770 mg) in 89% yield over two steps. 
1
H NMR (600 MHz; 
CDCl3):  8.72 (s, 1H, OCNHCCl3), 7.47 – 7.28 (m, 10H, OCH2Ph), 6.37 (d, J = 3.6 Hz, 1H, H-1 
of IdoA), 5.24 (d, J = 4.7 Hz, 1H, H-1 of GlcN), 4.96 (d, J = 10.5 Hz, 1H, OCH2Ph), 4.90 (t, J = 
4.4 Hz, 1H, H-2 of GlcN), 4.75 (d, J = 11.7 Hz, 1H, OCH2Ph), 4.71 (d, J = 10.5 Hz, 1H, 
OCH2Ph), 4.66 (d, J = 11.8 Hz, 1H, OCH2Ph), 4.63 (d, J = 4.2 Hz, 1H, H-5 of GlcN), 4.52 (dd, J 
= 12.3, 1.8 Hz, 1H, H-6 of GlcN), 4.13 (dd, J = 12.3, 4.3 Hz, 1H, H-6 of GlcN), 4.08 – 3.98 (m, 
3H, H-4 and H-5 of IdoA, H-4 of GlcN), 3.91 (dd, J = 10.2, 8.5 Hz, 1H, H-3 of IdoA), 3.69 (dd, J 
= 10.2, 3.6 Hz, 1H, H-2 of IdoA), 3.66 – 3.61 (m, 1H, H-3 of GlcN), 3.57 (s, 3H, CO2CH3), 2.89 
– 2.69 (m, 2H, COCH2CH2COCH3), 2.67 – 2.54 (m, 2H, COCH2CH2COCH3), 2.18 (s, 3H, 
COCH2CH2COCH3), 2.01 (s, 3H, COCH3), 0.82 (d, J = 2.5 Hz, 9H, SiC(CH3)3), -0.05 (s, 3H, 
SiCH3), -0.09 (s, 3H, SiCH3); 
13
C NMR (125 MHz; CDCl3):  206.5, 172.1, 170.2, 170.0, 160.7, 
137.7, 137.6, 128.7, 128.2, 128.1, 128.0, 127.9, 127.6, 97.7, 94.4, 78.2, 77.2, 76.7, 75.1, 75.0, 
73.0, 72.0, 71.9, 70.2, 69.0, 62.8, 61.9, 51.7, 38.0, 29.9, 28.0, 25.5, 20.1, 17.8, 4.7, 5.4; ESI-TOF 
HRMS m/z calcd for C42H55N3O15SiCl3 [M+Na]
+
: 997.2366; found: 997.2415. 
 
 
Methyl 3-O-benzyl-4-O-tert-butyldimethylsilyl--L-idopyranosyluronate-(14)-2-amino-3-
O-benzyl-1-O-(2-(2-((2S)-bicyclo[2.2.1]hept-5-en-2-ylmethoxy)ethoxy)ethyl)-2-deoxy--D-glu 
-copyranoside (16). Compound 5 (17 mg, 20 mol) was dissolved in anhydrous MeOH (0.80 
mL), and 1,3-propanedithiol (0.14 mL, 60 mol) and DIPEA (0.12 mL, 60 mol) were added 
dropwise.  Upon confirmation of partial disappearance of 5 by TLC, flame-dried K2CO3 (2.4 mg, 
20 mol) was added and the reaction mixture was stirred for 24 h at rt. The reaction was 
quenched with Dowex 5W-X8 (H
+ 
form), filtered through a pad of Celite, and concentrated under 
reduced pressure. Silica gel flash chromatography (1:1 hexanes:EtOAc) afforded the desired 
product (14 mg) in 93% yield. 
1
H NMR (500 MHz; CDCl3):  7.48 – 7.20 (m, 10H, OCH2Ph), 
6.17 – 5.88 (m, 2H, CH=CH of Nb), 5.25 (d, J = 4.5 Hz, 1H, H-1 of IdoA), 4.96 (d, J = 11.4 Hz, 
1H, OCH2Ph), 4.83 (d, J = 11.4 Hz, 1H, OCH2Ph), 4.68 – 4.51 (m, 3H, OCH2Ph, H-5 of IdoA), 
4.32 (d, J = 8.0 Hz, 1H, H-1 of GlcN), 4.09 – 3.76 (m, 5H, H-6 of IdoA, H-4 of IdoA, H-2 of 
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IdoA, OCH2 of PEG linker), 3.76 – 3.53 (m, 10H, H-2 of IdoA, H-6 of IdoA, OCH2 of PEG 
linker, CO2CH3), 3.47 – 3.32 (m, 4H, H-4 of GlcN, OCH2 of PEG linker, H-5 of GlcN, H-3 of 
GlcN), 2.84 – 2.68 (m, 3H, H-2 of GlcN, CH-CH=CH of Nb), 1.69 – 1.63 (m, 1H, CH of Nb), 
1.40 – 1.03 (m, 4H, CH2 of Nb), 0.82 (s, 9H, SiC(CH3)), -0.03 (d, J = 7.3 Hz, 7H, SiCH3); 
13
C 
NMR (125 MHz; CD3OD):  171.7, 140.1, 139.7, 137.7, 137.5, 129.2, 128.8, 128.4, 104.5, 102.3, 
84.1, 79.5, 77.7, 77.0, 75.2, 74.4, 72.8, 71.5, 71.4, 61.8, 57.8, 52.4, 45.8, 44.9, 42.8, 40.1, 30.6, 
26.1, 18.7, -4.5, -5.1; ESI-TOF HRMS: m/z calcd for C45H66NO13Si [M-H]
-
 856.4303; found: 
856.4326. 
 
 
Methyl 2-O-acetyl-3-O-benzyl-4-O-tert-butyldimethylsilyl--L-idopyranosyluronate-(14)-
2-acetylamido-3-O-benzyl-1-O-(2-(2-((2S)-bicyclo[2.2.1]hept-5-en-2-ylmethoxy)ethoxy)eth-
yl)-2-deoxy--D-glucopyranoside (17). Compound 5 (190 mg, 0.18 mmol) was dissolved in 
anhydrous MeOH (11 mL). 1,3-propanedithiol (1.1 mL, 5.4 mmol) and DIPEA (1.1 mL, 6.3 
mmol) were added dropwise, and the reaction mixture was stirred for 24 h at rt. The reaction was 
quenched with Dowex 5W-X8 (H
+ 
form), filtered through a pad of Celite, and concentrated under 
reduced pressure. Silica gel flash chromatography (30:2:1  20:2:1 EtOAc:MeOH:H2O) afforded 
the desired product (150 mg), and the resulting intermediate was dissolved in pyridine (2.8 mL). 
To this mixture, a solution of hydrazine monohydrate (1.2 mmol) and AcOH (9.9 mmol) in 
pyridine (17 mL) was added at rt. The reaction mixture was diluted with CH2Cl2 (10 mL), washed 
with cold water (15 mL), saturated NaHCO3 (15 mL), water (15 mL), and saturated brine (15 
mL). The combined organic fractions were dried over MgSO4 and concentrated under reduced 
pressure. Silica gel flash chromatography (20:2:1 EtOAc:MeOH:H2O) afforded the desired 
product (140 mg) in 87% yield over two steps. 
1
H NMR (500 MHz; CDCl3):  7.46 – 7.27 (m, 
10H, OCH2Ph), 6.14 – 5.98 (m, 2H, CH=CH of Nb), 5.31 (d, J = 4.4 Hz, 1H, H-1 of IdoA), 4.99 
(d, J = 11.2 Hz, 1H, OCH2Ph), 4.88 (q, J = 3.6 Hz, 1H, H-2 of IdoA), 4.80 – 4.68 (m, 2H, 
OCH2Ph, H-5 of IdoA), 4.67 – 4.55 (m, 2H, OCH2Ph), 4.36 (dt, J = 8.0, 4.1 Hz, 1H, H-1 of 
GlcN), 4.05 – 3.85 (m, 4H, H-4 of IdoA, H-6 of GlcN, H-5 of GlcN, OCH2 of PEG linker), 3.85 – 
3.34 (m, 15H, OCH2 of PEG linker, H-6 of GlcN, H-3 of IdoA, CO2CH3, H-3 of GlcN, H-4 of 
GlcN), 2.89 (dd, J = 10.0, 7.8 Hz, 1H, H-2 of GlcN), 2.81 – 2.67 (m, 2H, CH-CH=CH of Nb), 
2.01 (s, 3H, OCOCH3), 1.42 – 1.14 (m, 5H, CH and CH2 of Nb), 0.82 (s, 9H, SiC(CH3)), -0.08 (d, 
J = 7.3 Hz, 6H, SiCH3); 
13
C NMR (125 MHz; CDCl3):  170.2, 138.7, 137.8, 136.7, 128.5, 128.1, 
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127.9, 127.6, 97.8, 76.8, 76.2, 75.7, 75.5, 74.2, 72.7, 72.0, 70.7, 70.4, 69.3, 69.0, 61.7, 56.6, 51.9, 
45.1, 43.8, 41.7, 38.9, 38.6, 29.9, 25.7, 21.1, 17.9, -4.5, -5.4; ESI-TOF HRMS: m/z calcd for 
C47H70NO14Si [M-H]
-
 900.4565; found: 900.4568. 
 
 
Methyl 3-O-benzyl-2-O-sulfonato-4-O-tert-butyldimethylsilyl--L-idopyranosyluronate-(1 
4)-3-O-benzyl-1-O-(2-(2-((2S)-bicyclo[2.2.1]hept-5-en-2-ylmethoxy)ethoxy)ethyl)-2-deoxy-2-
sulfonatamido-6-O-sulfonato--D-glucopyranoside (18). Compound 16 (9.2 mg, 10 mol) was 
dissolved in freshly distilled pyridine (1.0 mL) and to this SO3•Py (50 mg, 0.32 mmol) and Et3N 
(0.20 mL) were added. The reaction mixture was stirred at rt for 24 h, refluxed at 50 C for 24 h, 
quenched with MeOH (1.0 mL), and concentrated to afford a golden syrup. Purification by 
Sephadex LH-20 gel filtration (1:1 CH2Cl2:MeOH), followed by silica gel flash chromatography 
(15:2:1  10:2:1  8:2:1 EtOAc:MeOH:H2O) gave the desired product (8.7 mg) in 78% yield. 
1
H NMR (500 MHz; CD3OD):  7.51 – 7.50 (m, 2H, OCH2Ph), 7.43 – 7.41 (m, 2H, OCH2Ph), 
7.37 – 7.34 (m, 2H, OCH2Ph), 7.30 – 7.26 (m, 3H, OCH2Ph), 7.23 – 7.22 (m, 1H, OCH2Ph), 6.11 
– 6.04 (m, 2H, CH=CH of Nb), 5.30 (s, H-1 of IdoA), 4.98 (d, J = 12.5 Hz, 1H, OCH2Ph), 4.87 
(d, J = 11.5 Hz, 1H, OCH2Ph), 4.78 (d, J = 6 Hz, 1H, H-1 of GlcN), 4.67 (d, J = 11.5 Hz, 1H, 
OCH2Ph), 4.59 (d, J = 12.5 Hz, 1H, OCH2Ph), 4.43 (s, 1H, H-2 of IdoA), 4.37 – 4.28 (m, 2H, H-
6, H-6 of GlcN), 4.13 – 4.12 (m, 1H, H-4 of GlcN), 4.05 – 4.03 (m, 1H, H-5 of GlcN), 3.96 – 
3.93 (m, 1H, H-4 of IdoA), 3.81 – 3.78 (m, 2H, H-3 of IdoA, OCH2 of PEG linker), 3.73 – 3.71 
(m, 2H, OCH2 of PEG linker), 3.69 – 3.56 (m, 5H, OCH2 of PEG linker), 3.54 – 3.51 (m, 1H, H-2 
of GlcN), 3.45 – 3.35 (m, 2H, OCH2 of PEG linker), 3.15 (s, 3H, CO2CH3), 2.77 (s, 1H, CH-
CH=CH of Nb), 2.72 (s, 1H, CH-CH=CH of Nb), 2.11 (s, 3H, OCOCH3), 1.98 (s, 3H, OCOCH3), 
1.72 – 1.68 (m, 1H, CH of Nb), 1.38 – 1.21 (m, 3H, CH2 of Nb), 1.15 – 1.12 (m, 1H, CH2 of Nb), 
0.76 (s, 9H, SiC(CH3)), -0.17 (s, 3H, SiCH3), -0.24 (s, 3H, SiCH3); 
13
C NMR (125 MHz; 
CD3OD):  172.8, 141.1, 140.4, 138.7, 131.6, 131.0, 130.6, 130.4, 130.3, 130.2, 130.0, 129.4, 
104.3, 100.1, 80.9, 78.0, 77.0, 72.7, 72.4, 71.0, 70.7, 56.2, 53.5, 46.9, 46.0, 43.8, 41.1, 31.7, 27.4, 
19.9, -3.0, -4.4; ESI-TOF HRMS: m/z calcd for C45H66NO22S3Si [M-H]
-
 1016.2597; found: 
1016.2583. 
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Methyl 2-O-sulfonato-3-O-benzyl-4-O-tert-butyldimethylsilyl--L-idopyranosyluronate-(1 
4)-2-acetylamido-3-O-benzyl-1-O-(2-(2-((2S)-bicyclo[2.2.1]hept-5-en-2-ylmethoxy)ethoxy) 
ethyl)-2-deoxy-6-O-sulfonato--D-glucopyranoside (19). To a solution of compound 16 (130 
mg, 0.15 mmol) in anhydrous MeOH (8.4 mL) at ambient temperature were added Ac2O (0.30 
mL, 3.0 mmol) and Et3N (0.50 mL). Additional amounts of Ac2O (0.30 mL, 3.0 mmol) were 
added every hour until complete conversion to the desire product was observed by TLC (at least 4 
h). The reaction mixture was directly loaded onto a Sephadex LH-20 gel filtration column and 
eluted with 1:1 CH2Cl2:MeOH. The N-acetylated intermediate was dissolved in freshly distilled 
pyridine (8.1 mL), and SO3•Py (450 mg, 3.3 mmol) and Et3N (1.6 mL) were added. The reaction 
mixture was stirred at rt for 24 h, refluxed at 50 C for 24 h, quenched with MeOH (5.0 mL), and 
concentrated to afford a golden syrup. Purification by Sephadex LH-20 gel filtration (1:1 
CH2Cl2:MeOH), followed by silica gel flash chromatography (10:2:1 EtOAc:MeOH:H2O) gave 
the desired product (130 mg) in 85% yield over two steps. 
1
H NMR (500 MHz; CD3OD):  7.53 – 
7.10 (m, 10H, OCH2Ph), 6.12 – 5.95 (m, 2H, CH=CH of Nb), 5.35 (s, 1H, H-1 of IdoA), 4.84 (m, 
2H, H-5 of IdoA, OCH2Ph), 4.73 (d, J = 11.2 Hz, 1H, OCH2Ph), 4.60 (d, J = 11.6 Hz, 1H, 
OCH2Ph), 4.55 (d, J = 8.3 Hz, 1H, H-1 of GlcN), 4.52 (dd, J = 2.1, 1.1 Hz, 1H, H-2 of IdoA), 
4.47 (d, J = 11.2 Hz, 1H, OCH2Ph), 4.41 (dd, J = 11.3, 2.2 Hz, 1H, OCH2 of PEG linker), 4.29 
(dd, J = 11.2, 5.0 Hz, 1H, OCH2 of PEG linker), 4.00 – 3.87 (m, 4H, H-4 of IdoA, H-2 of GlcN, 
H-3 of GlcN, H-6 of GlcN), 3.86 (t, J = 1.8 Hz, 1H, H-3 of IdoA), 3.79 – 3.48 (m, 11H, H-6 of 
GlcN, OCH2 of PEG linker, H-4 of GlcN, H-5 of GlcN), 3.46 – 3.36 (m, 1H, OCH2 of PEG 
linker), 3.33 (s, 3H, CO2CH3), 2.74 (d, J = 31.6 Hz, 2H, CH-CH=CH of Nb), 1.85 (d, J = 1.2 Hz, 
3H, NHCOCH3), 1.67 (d, J = 4.5 Hz, 1H, CH of Nb), 1.39 – 1.04 (m, 4H, CH2 of Nb), 0.78 (d, J 
= 1.2 Hz, 9H, SiC(CH3)), -0.11 (dd, J = 47.6, 1.1 Hz, 6H, SiCH3); 
13
C NMR (125 MHz; CD3OD): 
 173.3, 172.1, 139.7, 139.2, 137.7, 137.5, 129.9, 129.5, 129.1, 128.6, 102.6, 99.2, 82.3, 77.1, 
76.2, 75.7, 75.3, 74.1, 72.8, 71.5, 71.4, 70.1, 69.7, 67.8, 56.5, 52.4, 45.9, 44.9, 42.8, 40.0, 30.7, 
26.2, 23.0, 18.9, -4.2, -5.4; ESI-TOF HRMS: m/z calcd for C47H67NO20NaSiS2 [M+Na]
+
 
1080.3365; found: 1080.3392. 
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Methyl 3-O-benzyl-4-O-tert-butyldimethylsilyl--L-idopyranosyluronate-(14)-2-acetyl-
amido-3-O-benzyl-1-O-(2-(2-((2S)-bicyclo[2.2.1]hept-5-en-2-ylmethoxy)ethoxy)ethyl)-2-de-
oxy--D-glucopyranoside (20). To a solution of compound 16 (130 mg, 0.15 mmol) in 
anhydrous MeOH (8.4 mL) at ambient temperature were added Ac2O (0.30 mL, 3.0 mmol) and 
Et3N (0.50 mL). Additional amounts of Ac2O (0.30 mL, 3.0 mmol) were added every hour until 
complete conversion to the desired product was observed by TLC (at least 4 h). Purification by 
Sephadex LH-20 gel filtration (1:1 CH2Cl2:MeOH), followed by silica gel flash chromatography 
(20:2:1 EtOAc:MeOH:H2O) gave the desired product (140 mg) in quantitative yield. 
1
H NMR 
(600 MHz; CDCl3):  7.36 – 7.09 (m, 10H, OCH2Ph), 6.12 – 5.87 (m, 2H, CH=CH of Nb), 5.11 
(s, 1H, H-1 of IdoA), 4.76 – 4.72 (m, 1H, H-1 of GlcN), 4.70 (t, J = 2.7 Hz, 1H, H-4 of IdoA), 
4.68 – 4.56 (m, 2H, OCH2Ph), 4.51 – 4.43 (m, 2H, OCH2Ph), 4.00 – 3.92 (m, 1H, H-3 of IdoA), 
3.91 – 3.80 (m, 2H, OCH2 of PEG linker, H-6 of GlcN), 3.80 – 3.17 (m, 19H, H-6 of GlcN, H-2 
of GlcN, H-3 of GlcN, H-4 of GlcN, H-5 of GlcN, H-2 of IdoA, H-5 of IdoA, OCH2 of PEG 
linker, CO2CH3), 2.75 – 2.46 (m, 2H, CH-CH=CH of Nb), 1.67 (d, J = 4.2 Hz, 3H, NHCOCH3), 
1.64 – 1.53 (m, 1H, CH of Nb), 1.30 – 1.13 (m, 4H, CH2 of Nb), 0.71 (s, 9H, SiC(CH3)), -0.15 (d, 
J = 9.3 Hz, 6H, SiCH3); 
13
C NMR (125 MHz; CDCl3):  170.4, 169.7, 138.6, 137.5, 136.8, 136.6, 
128.8, 128.4, 128.2, 127.4, 107.3, 101.6, 100.9, 78.7, 77.0, 76.4, 75.7, 75.5, 72.6, 72.5, 71.0, 70.7, 
70.4, 69.8, 69.1, 68.8, 67.2, 62.7, 52.1, 45.2, 43.8, 41.7, 38.8, 30.0, 29.9, 25.6, 23.3, 17.9, -4.7, -
5.4; ESI-TOF HRMS: m/z calcd for C47H69NaNO14Si [M+Na]
+
 922.4380; found: 922.4385. 
 
 
Methyl 2-O-acetyl-3-O-benzyl-4-O-tert-butyldimethylsilyl--L-idopyranosyluronate-(14)-
3-O-benzyl-1-O-(2-(2-((2S)-bicyclo[2.2.1]hept-5-en-2-ylmethoxy)ethoxy)ethyl)-2-deoxy-2-
sulfonatamido-6-O-sulfonato--D-glucopyranoside (21). To a solution of compound 17 (22 
mg, 0.020 mmol) in freshly distilled pyridine (2.3 mL) were added SO3•Py (110 mg, 0.60 mmol) 
and Et3N (0.5 mL). The reaction mixture was stirred at rt for 24 h and refluxed at 50 C for 24 h, 
quenched with MeOH (1.0 mL), and concentrated to afford a golden syrup. Purification by 
Sephadex LH-20 gel filtration (1:1 CH2Cl2:MeOH), followed by silica gel flash chromatography 
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(15:2:1  10:2:1 EtOAc:MeOH:H2O) gave the desired product (26 mg) in 78% yield. 
1
H NMR 
(600 MHz; CD3OD): δ 7.79 – 7.03 (m, 10H, OCH2Ph), 6.25 – 5.94 (m, 2H, CH=CH of Nb), 
5.31 (d, J = 4.4 Hz, 1H, H-1 of IdoA), 5.05 – 4.76 (m, 4H, H-2 of IdoA, H-5 of IdoA, OCH2Ph), 
4.75 – 4.64 (m, 1H, OCH2Ph), 4.65 – 4.47 (m, 2H, OCH2Ph, H-1 of GlcN), 4.38 (m, 1H, H-6 of 
GlcN), 4.20 (m, 1H, H-6 of GlcN), 4.07 – 3.85 (m, 4H, H-2 of IdoA, H-2 of GlcN, H-2 of GlcN, 
OCH2 of PEG linker), 3.86 – 3.71 (m, 1H, OCH2 of PEG linker), 3.71 – 3.45 (m, H, 11H, H-3 of 
IdoA, H-3 of GlcN, H-5 of GlcN, OCH2 of PEG linker), 3.40 (s, 3H, CO2CH3), 2.81 – 2.74 (m, 
2H, CH-CH=CH of Nb), 2.07 (s, 3H, OCOCH3), 1.52 – 1.10 (m, 5H, CH and CH2 of Nb), 0.83 (s, 
9H, SiC(CH3)), -0.09 (s, 3H, SiCH3), -0.13 (s, 3H, SiCH3); 
13
C NMR (125 MHz; CDCl3):  173.3, 
172.0, 171.8, 139.8, 139.1, 137.7, 137.5, 102.8, 99.2, 82.1, 79.8, 77.1, 76.6, 76.2, 75.9, 75.3, 75.2, 
73.2, 71.5, 71.4, 71.3, 71.0, 70.1, 69.8, 69.4, 67.3, 56.3, 52.4, 45.9, 44.9, 42.8, 40.0, 37.4, 36.0, 
30.7, 23.0, 21.2, 18.7, -4.3, -5.4; ESI-TOF HRMS: m/z calcd for C47H67NO20NaSiS2 [M+Na]
+
 
1080.3365; found: 1080.3392. 
 
 
Protected HS glycopolymers (22 – 25). Monomers 18 – 21 were converted into polymers 22 – 
25, which contain the following functional groups: R1 = SO3
-
, R2 = SO3
-
, R3 = SO3
-
 (1); R1 = SO3
-
, 
R2 = SO3
-
, R3 = Ac
-
 (2); R1 = H, R2 = H, R3 = Ac (3); R1 = H, R2 = SO3
-
, R3 = SO3
-
 (4). In a 
typical polymerization, a small vial was charged with monomer (18 – 21; 6.0 mg, 5.0 mol) and a 
small stir bar under the flow of argon. To this was added degassed dichloroethane (DCE)/MeOH 
(10:1, 0.025 M) and bis-pyridine Grubbs catalyst ((H2IMes)(Py)2(Cl)2Ru=CHPh)
4
 in DCE (5 
mg/mL stock solution, 24 L, 0.11 mol) by syringe at rt. The reaction mixture was stirred at rt 
for 1 h, quenched with ethyl vinyl ether (0.10 mL), and diluted with diethyl ether (1.0 mL) and 
hexanes (0.50 mL) to obtain a white precipitate. The mixture was centrifuged to remove the 
organic layer, and the resulting white solid (83 – 98% conversion) was dried in vacuo. 1H NMR 
confirmed disappearance of the norbornene olefinic peaks at 6.04 – 6.11 ppm. The protected 
polymers were characterized by size exclusion chromatography multi-angle light scattering (SEC-
MALS) using a system equipped with an MZ-Gel SDplus organic column (10E5Å, MZ 
Analysentechnik), a light scattering detector (miniDAWN, Wyatt Technology), and a refractive 
index detector (TREOS, Wyatt Technology), and 0.2 M LiBr in DMF as the mobile phase. 
1
H 
NMR (500 MHz; D2O): 
 
7.49 – 7.15 (m, 10H), 5.42 (br, 1H), 5.18 (br, 1H), 4.75 (br, 1H), 4.65 – 
4.51 (m, 2H), 4.38 (br, 1H), 4.05 – 3.84 (m, 4H), 3.86 (br, 1H), 3.79 – 3.50 (m, 13H), 3.46 (br, 
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1H), 3.31 (br, 3H) 3.30 – 3.25 (m, 2H), 2.49 (br, 2H), 1.94 (br, 3H), 1.79 – 1.07 (m, 5H), 0.77 (br, 
9H), -0.07 (br, 3H), -0.17 (br, 3H). 
 
 
2-O-Sulfonato--L-idopyranosyluronate-(14)-1-O-(2-(2-((2S)bicyclo[2.2.1]hept-5-en-2-
ylmethoxy)ethoxy)ethyl)-2-deoxy-2-sulfonatamido-6-O-sulfonato--D-glucopyranoside (26). 
Compound 18 (14 mg, 0.013 mmol) was dissolved in THF (1.3 mL), and TMSOK (33 mg, 0.26 
mmol) was added to the reaction mixture. The reaction was stirred for 24 h at rt and quenched 
with MeOH (1.0 mL). The crude reaction mixture was loaded directly onto a Sephadex G-25 gel 
filtration column and eluted with 100% H2O, and fractions were combined, lyophilized, and 
subjected to hydrogenation. The intermediate was dissolved in a 3:2 mixture of 80 mM phosphate 
buffered saline (2.4 mL, pH = 7.0) and MeOH (0.80 mL). To this, Pd(OH)2/charcoal (80 mg, 8x 
by weight of starting material) was added, and the reaction was carried out under 1 atm H2 gas for 
3 d. The reaction mixture was filtered using a vacuum filtration system (0.45 m PES membrane, 
VWR) and desalted on a Sephadex G-25 column in 100% H2O to obtain the desired product 60% 
yield after lyophilization. 
1
H NMR (500 MHz, D2O)  5.24 (s, 1H, H-1 of IdoA), 4.83 (d, J = 2.7 
Hz, 1H, H-5 of IdoA), 4.73 (d, J = 8.2 Hz, 1H, H-1 of GlcN), 4.44 (m, 1H, H-6 of GlcN), 4.34 (m, 
2H, H-6 of GlcN, H-2 of IdoA), 4.10 (m, 2H, H-3 of IdoA, H-4 of IdoA), 4.01 – 3.71 (m, 11H, 
OCH2 of PEG linker, H-3 of GlcN, H-4 of GlcN, H-5 of GlcN), 3.44 – 3.31 (m, 2H, OCH2 of 
PEG linker), 3.16 (m, 1H, H-2 of GlcN), 2.28 – 2.20 (m, 2H, bridgehead CH2 of Nb), 1.82 (s, 2H, 
CH2 of Nb), 1.59 (s, 2H, CH2 of Nb), 1.48 – 1.36 (m, 2H, CH of Nb), 1.27 – 1.19 (m, 2H, CH2 of 
Nb), 1.08 (s, 1H, CH of Nb); ESI-TOF HRMS: m/z calcd for C24H37Na3NO22S3 [M+3Na-H]
2+
 
856.0662; found: 856.0624. 
 
 
Deprotected HS glycopolymers (1 – 4). Polymers 22 – 25 were deprotected to obtain final 
polymers 1 – 4, which contain the following functional groups: R1 = SO3
-
, R2 = SO3
-
, R3 = SO3
-
 
(1); R1 = SO3
-
, R2 = SO3
-
, R3 = Ac
-
 (2); R1 = H, R2 = H, R3 = Ac (3); R1 = H, R2 = SO3
-
, R3 = SO3
-
 
(4). In a typical reaction, polymer (11 mg, 10 mol per unit) was dissolved in THF (1.0 mL), and 
O
O
H
2
O
OSO3
-OH
OH
-O2C
O
O
OSO3
-
HO NHSO3
-
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TBAI (7.0 mg, 20 mol) and TMSOK (25 mg, 0.20 mmol) were added. The reaction was stirred 
for 24 h at rt and quenched with MeOH (1.0 mL). The crude reaction mixture was loaded directly 
onto a Sephadex G-25 gel filtration column and eluted with 100% H2O. The polymer-containing 
fractions were combined, lyophilized, and subjected to hydrogenation. In a typical hydrogenation 
reaction, the polymer from the previous reaction was dissolved in a 3:2 mixture of 80 mM 
phosphate buffered saline (0.9 mL, pH = 7.0) and MeOH (0.60 mL). To this, Pd(OH)2/charcoal 
(84 mg, 8x weight of polymer) was added, and the reaction was carried out under 1 atm H2 gas 
for 3 d. Samples were filtered using a vacuum filtration system (0.45 m PES membrane, VWR) 
and desalted on a Sephadex G-25 column in 100% H2O to obtain the desired polymers in 35 – 
55% yield after lyophilization. 
1
H NMR showed disappearance of the benzyl and methyl ester 
peaks at 7.79 – 7.03 ppm and 3.40 ppm, respectively. Deprotected polymers were characterized 
by SEC-MALS using a system equipped with an OHpak water column (SB-804 HQ, Shodex), a 
light scattering detector (miniDAWN, Wyatt Technology), and a refractive index detector 
(TREOS, Wyatt Technology), and 3 mM NaN3 and 6 mM NaNO3 in H2O as the mobile phase. 
1
H 
NMR (500 MHz; D2O): 
 
5.03 (br, 1H), 4.44 (br, 1H), 4.25 – 4.20 (m, 1H), 4.18 – 4.11 (m, 2H), 
3.92 (br, 1H), 3.84 (br, 2H), 3.75 – 3.40 (m, 12H), 3.34 (br, 1H), 3.19 (br, 1H), 1.91 (br, 3H), 1.72 
(br, 1H), 1.48 – 0.88 (m, 6H). 
 
3-3. Direct and Competitive Enzyme-Linked Immunosorbent Assay (ELISA) 
A 96-well heparin-binding plate (BD Biosciences) was coated with 25 g/mL of heparin 
(Neoparin) for 12 h at rt. Wells were rinsed with phosphate-buffered saline (PBS) and blocked 
with 10% fetal bovine serum (FBS) in PBS for 1 h at 37 °C. For the direct ELISA, various 
concentrations of RANTES (0.50 – 1024 nM; R&D Systems) were serially diluted in 1% BSA in 
PBS and incubated in each well for 1.5 h at 37 °C. For the competitive ELISA, RANTES (at 12 
nM, the pre-determined EC50; Figure S1) was pre-incubated (3 h, 37 °C) with various 
concentrations of heparin (0.010 – 40 g/mL) or glycopolymers 1 – 4 (0.10 – 180 g/mL), and 
the co-mixture was added to the 96-well plate for 1.5 h at 37 °C. Wells were washed three times 
with PBST (PBS + 0.1% Tween-20), incubated with a mouse anti-RANTES antibody (R&D 
Systems) for 1 h at 37 °C, washed three times with PBST, and incubated with a horseradish 
peroxidase (HRP)-conjugated anti-mouse IgG antibody (GE Healthcare Life Sciences) for 1 h at 
37 °C. After three washes with PBST, RANTES binding was detected using a 3,3',5,5'-
tetramethylbenzidine (TMB) substrate kit (Thermo Scientific) according to the manufacturer’s 
instructions. Fluorescence was measured at 450 nm using a Victor 3 plate reader (PerkinElmer). 
The half-maximal effective concentration (EC50) and half maximal inhibitory concentration (IC50) 
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were calculated using KaleidaGraph software (Synergy). IC50 values reported in the paper are for 
both the mass and molar concentrations of antagonist.  IC50 values were also corrected for ligand 
valence (Table S2) by calculating the mass percentage of the disaccharide epitope contributing to 
each disaccharide-norbornyl linker unit, and then dividing by the molecular weight of the 
disaccharide epitope. 
 
3-4. Cell Culture 
L1.2 cells (mouse pre-B lymphocytes) stably transfected with CCR3, CCR5, or vector only, were 
kindly provided by Dr. Osamu Yoshie (Kinki University, School of Medicine, Japan). Cells were 
maintained in RPMI 1640 (Invitrogen) supplemented with 10% FBS, 100 g/mL 
penicillin/streptomycin (Invitrogen), and 50 μM 2-mercaptoethanol (Sigma Aldrich). Cells were 
routinely analyzed by flow cytometry (FACSCalibur, Beckman Dickenson; see section 2-6) to 
verify that cultures expressed adequate levels of chemokine receptor (>90%) for migration and 
cell binding assays. 
 
3-5. Cell Migration Assay  
Experiments were performed using ChemoTx chambers (Neuroprobe). L1.2 cells (wild-type or 
stably-transfected with CCR3 or CCR5) were harvested and washed twice in flow cytometry 
buffer (Hank’s Balanced Salt Solution (HBSS) with 2.5 mg/mL bovine serum albumin (BSA) and 
10 mM HEPES). Human RANTES (R&D Systems) was serially diluted in flow cytometry buffer 
(0.5 – 1024 nM), and 30 L of each dilution was added to the bottom wells of the ChemoTx 
chamber. Alternatively, in competitive migration assays, 1 or 10 nM of RANTES was pre-
incubated with various concentrations of heparin or glycopolymer 1 (0.020 – 4.0 g/mL) for 30 
min at rt, and the same volume of each solution was added to the bottom wells. The sample plate 
was fitted with a 5-m pore filter, and 106 cells (50 L) were placed on top of each well. Cells 
were allowed to migrate through the filter for 4 h at 37 C and 5% CO2. Subsequently, non-
migrating cells were removed from the top of the filter by manual scraping; cells adhering to the 
filter were dislodged using 20 µL of 2.5 mM EDTA for 30 min at rt. Migrated cells were 
transferred (500 x g, 5 min) to a 96-well black-walled clear-bottomed plate (Corning) using a 
funnel plate (Neuroprobe). Cells were lysed at -80 C and stained with CyQUANT dye 
(Invitrogen) as described in the product literature. Fluorescence was measured at 535 nm using a 
Victor 3 plate reader (PerkinElmer).   
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3-6. Chemokine Cell Binding Assay  
3 x 10
6
 L1.2 cells (wild-type or stably-transfected with CCR3) were washed twice with flow 
cytometry buffer and incubated with RANTES (100 nM in flow cytometry buffer) for 45 min at 
rt. Alternatively, cells were incubated with RANTES (100 nM in flow cytometry buffer) 
previously treated with various concentrations of heparin or glycopolymer 1 (0.02 – 2 g/mL) for 
30 min at rt. Cells were spun twice (500 x g, 5 min) through 100% FBS (1.0 mL) to remove 
excess reagent and stained with phycoerythrin (PE)-conjugated anti-RANTES (1 test) in FACS 
buffer (100 L) for 1 h at 4 C. Cells were again spun twice through 100% FBS (1.0 mL) and 
resuspended in flow cytometry buffer (500 L) for flow cytometry analysis. Immediately before 
analysis, 7-amino-actinomycin-D (7-AAD, 5 L, eBioscience) was added to evaluate cell 
viability. Cells were analyzed for PE intensity on a FACSCalibur flow cytometer (Beckman 
Dickenson, Caltech Flow Cytometry Facility) with 10,000 cell events per sample. Data analysis 
was performed using FlowJo (Tree Star Inc.). 
 
3-7. Chromogenic Assay for the Measurement of Antithrombin Activity 
Factor Xa Activity: The BIOPHEN Heparin Anti-Xa (2 stages) USP/EP kit (Aniara) was used to 
determine factor Xa activity. This chromogenic anti-Xa method for measuring homogeneous 
heparin in purified systems is in compliance with Pharmacopoeias (USP, EP) and FDA guidelines. 
All reagents were prepared according to manufacturer’s instructions and incubated at 37 °C for 
15 min. Varying concentrations of heparin (Neoparin) or glycopolymers 1 – 4 (40 uL) and 
antithrombin (40 uL) were added to a microcentrifuge tube, mixed, and incubated at 37 °C for 2 
min. Factor Xa (40 uL) was added to the solution, incubated at 37 °C for exactly 2 min, and then 
the factor Xa chromogenic substrate (40 µL) was added. After 2 min, the reaction was quenched 
with citric acid (20 g/L, 240 µL), and the absorbance was measured at 405 nm. The sample blank 
was obtained by mixing the reagents in reverse order, and the resulting value was deducted from 
the absorbance values measured in the assay.    
Thrombin (Factor IIa) Activity: The BIOPHEN Heparin Anti-IIa (2 stages) USP/EP kit (Aniara) 
was used to determine factor IIa activity. This chromogenic anti-IIa method was conducted 
according to the same procedure used for factor Xa. 
 
  
 S25 
4. References 
 
(1) (a) Orgueira, H. A.; Bartolozzi, A.; Schell, P.; Litjens, R. E. J. N.; Palmacci, E. R.; Seeberger, 
P. H. Chem. Eur. J. 2003, 9, 140. (b) Lohman, G. J. S.; Hunt, D. K.; Hogermeier, J. A.; 
Seeberger, P. H. J. Org. Chem. 2003, 68, 7559. 
(2) Lee, S. G.; Brown, J. M.; Rogers, C. J.; Matson, J. B.; Krishnamurthy, C.; Rawat, M.; Hsieh-
Wilson, L. C. Chem. Sci. 2010, 1, 322. 
(3) Gavard, O.; Hersant, Y.; Alais, J.; Duverger, V.; Dilhas, A.; Bascou, A.; Bonnaffe, D. Eur. J. 
Org. Chem. 2003, 2003, 3603.  
(4) Scholl, M.; Ding, S.; Lee, C. W.; Grubbs, R. H. Org. Lett. 1999, 1, 953. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

















